RxDoctor Payments Data

Timothy Rhyme, MD

Family Medicine · Vineland, NJNPI 1992734974

Payments from drug & device makers

$5,771in general payments, 2019–2025

Across 392 payments — averaging $14.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$643
  • AbbVie$593
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$419
  • Abbott$403
  • Boehringer Ingelheim$293
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$5,63398%
  • Education$1382%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,771 in reported general payments places this provider in the 90th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$114,917
Medicare patients
343
Services billed
905

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$99,445
JanuviaSitagliptin Phosphate69$93,583
MounjaroTirzepatide41$75,214
JardianceEmpagliflozin38$58,117
TrulicityDulaglutide28$56,008
FarxigaDapagliflozin Propanediol45$52,586
EliquisApixaban49$44,117
LinzessLinaclotide25$21,144
XareltoRivaroxaban25$18,843
Tresiba Flextouch U-200Insulin Degludec19$16,951
EntrestoSacubitril/Valsartan18$13,026
MyrbetriqMirabegron20$12,907
OxycontinOxycodone Hcl12$11,999
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$8,692
Pitavastatin Calcium11$7,866

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$249$131,22269 claims
Novo NordiskOzempic$643$99,44573 claims
MerckJanuvia$104$93,58369 claims
Boehringer IngelheimJardiance, Combivent Respimat$293$63,89150 claims
AstraZenecaFarxiga, Symbicort$1,032$55,14156 claims
PfizerEliquis$37$44,11749 claims
AbbVieLinzess$593$21,14425 claims
Johnson & JohnsonXarelto$50$18,84325 claims
NovartisEntresto$57$13,02618 claims
Astellas Pharma US IncMyrbetriq$246$12,90720 claims
GSKBreo Ellipta$142$5,86216 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$98$4,14311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Vineland

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →